<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01097070</url>
  </required_header>
  <id_info>
    <org_study_id>Bevirimat Study 206</org_study_id>
    <nct_id>NCT01097070</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days</brief_title>
  <official_title>A Phase II Multicenter, Open-label, Randomized, Parrallel Group Study to Assess the Pharmacokinetics of Bevirimat (BVM) 100 mg Tablets Administered to HIV-1 Positive Patients for 15 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myrexis Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myrexis Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics
      (behavior in the body) of bevirimat administered for 15 days to HIV-positive individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure bevirimat blood plasma concentrations to calculate the pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life when bevirimat is administered as 2 x 100 mg tablets BID, 3 X 100 mg tablets QD, 4 X 100 mg tablets QD for 15 days</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure bevirimat blood plasma concentrations following the administration of bevirimat 2 X 100 mg, 3 x 100 mg, or 4 x 100 mg tablets after a standardized meal. The pharmacokinetic parameters of AUC, Cmax, Cmin, and half-life will be calculated.</measure>
    <time_frame>Day 15</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Bevirimat 200 mg twice daily, 15 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevirimat 300 mg once daily, 15 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bevirimat 400 mg once daily, 15 days</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevirimat</intervention_name>
    <arm_group_label>Bevirimat 200 mg twice daily, 15 days</arm_group_label>
    <arm_group_label>Bevirimat 300 mg once daily, 15 days</arm_group_label>
    <arm_group_label>Bevirimat 400 mg once daily, 15 days</arm_group_label>
    <other_name>MPC-4326</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have documentation of HIV-1 infection in their medical records (documentation of any
             prior plasma viremia is acceptable).

          -  Have a CD4+ lymphocyte count &gt;/= 100 cells/mm3.

          -  Have a screening plasma HIV-1 RNA value, measured by the Roche Amplicor assay, of &lt;400
             copies/mL.

          -  Be receiving an ARV therapy regimen containing at least 3 drugs which has been
             unchanged for at least 8 weeks prior to screening, and which is to be continued
             through Day 15 of the study.

          -  Be informed of the nature of the study and provide written informed consent.

          -  Be legally competent and able to communicate effectively with study personnel.

          -  Be able and willing to comply with outpatient visits.

        Exclusion Criteria:

          -  Presence of any acute illness within 14 days prior to study entry.

          -  Presence of any AIDS-related opportunistic infection (Category C according to the CDC
             Classification System for HIV-1 Infection, 1993 Revised Version) that is unstable in
             the Investigator's opinion or diagnosed in the 30 days prior to study entry.

          -  Patients who are, in the opinion of the Investigator, unable to comply with the dosing
             schedule and protocol evaluations.

          -  Patients with malabsorption syndromes affecting drug absorptions (e.g. Crohn's
             disease, chronic pancreatitis).

          -  Patients with systolic blood pressure &lt; 90 mmHg or &gt; 160 mmHg or diastolic blood
             pressure &lt; 50 mmHg or &gt; 110 mmHg.

          -  A history of seizures (excluding pediatric febrile seizures) or current administration
             of prophylactic anti-seizure medication for the indication of seizures or
             seizure-related conditions.

          -  A history of cerebrovascular accident (CVA) or transient ischemic attacks (TIA).

          -  Patients who have received radiation therapy or cytotoxic chemotherapeutic agents
             within 4 weeks prior to first dose of study drug.

          -  Patients who have received treatment with immunomodulating agents such as IL-2,
             alpha-interferon, beta-interferon, or gamma-interferon within 4 weeks prior to first
             dose of study drug.

          -  Receipt of an investigational drug or product, or participation in a drug study within
             a period of 30 days prior to receiving study medication.

          -  Bupropion-containing products require at least a 14-day washout period and will not be
             approved for co-administration.

          -  Rifampin or other rifamycin products require at least a 28-day washout period and will
             not be approved for coadministration.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Beelen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Myrexis Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob P Lalezari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quest Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary J Richmond, MD, PA</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_official>
    <last_name>Melanie A Thompson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Research Consortium of Atlanta</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Calvin J Cohen, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community Research Initiative of New England</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gary J. Richmond, MD, PA</name>
      <address>
        <city>Ft. Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research Consortium of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Research Initiative of New England</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2010</study_first_submitted>
  <study_first_submitted_qc>March 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2010</study_first_posted>
  <last_update_submitted>March 30, 2010</last_update_submitted>
  <last_update_submitted_qc>March 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andrew Beelen, MD., Study Director</name_title>
    <organization>Myriad Pharmaceuticals, Inc.</organization>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

